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ABSTRACT 
Anti-tubercular drugs induced hepatotoxicity, which is a serious problem and it was reported that worldwide 2-32% of TB patients experience 
drug induced hepatotoxicity (DIH) during the course of the treatment. A 65 year old male, 47 kg weight and chronic alcoholic was brought to a 
tertiary care hospital in semi-conscious condition with chief complains of vomiting, cough with expectoration, loss of appetite, shortness of 
breath, fever (on & off) since 4 days. He had a history of smear positive pulmonary koch’s 10 days back and was taking regular first line anti-
tubercular drug therapy (Isoniazid, Rifampicin, Pyrazinamide and Ethambutol). In this case, the patient was also chronic alco hol consumer and 
a known case of chronic obstructive pulmonary disease (COPD) since 2 years. After 10 days of anti-tubercular drug therapy, patient was found 
to develop hepatotoxicity with the findings of elevated total bilirubin and liver enzymes level. Viral markers for hepatitis,  including hepatitis B 
viruses (HBV), hepatitis C viruses (HCV), human immunodeficiency virus (HIV), were all are non-reactive. Physician found provisional diagnosis 
of anti-tubercular drugs with alcohol induced hepatitis. Patient was on hold of previous anti-tubercular drugs therapy. Although it was started 
modified anti-tubercular drugs (Streptomycin, Levofloxacin, Ethambutol) therapy along with liver tonics. Upon normalization of patient 
conditions, physician started first line anti-tubercular drug therapy containing Rifampicin, Isoniazid, Pyrazinamide, Ethambutol and Pyridoxine 
with continued liver tonics. Routine monitoring of liver enzymes, total bilirubin were followed up till discharged. Such type of case studies with 
confirmed pulmonary koch’s conditions suggested to follow alcohol withdrawal with standard treatment and standard care to achieve a 
favorable outcome. 
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INTRODUCTION 
As per world health organization (WHO), tuberculosis (TB) is 
affecting one third of the population worldwide and one out 
of four adult male deaths is attributed to TB1,2. The first line 
anti-TB drugs have the potentiality to cause hepatotoxicity. 
From first line anti-TB drugs, isoniazid (INH), rifampin (RIF), 
and pyrazinamide (PZA) causes hepatotoxicity2-5. The risk 
factors for anti-TB induced hepatotoxicity includes high 
alcohol intake, older age, pre-existing chronic liver disease, 
chronic viral infection due to hepatitis B (HBV) and hepatitis 
C viruses (HCV), human immunodeficiency virus (HIV) 
infection, advanced TB, Asian ethnicity, concomitant 
administration of enzyme-inducers, inappropriate use of 
drugs and poor nutritional status2,6,7.  
Tuberculosis and chronic obstructive pulmonary disease 
(COPD) are two important causes of mortality and morbidity 
in our country and are among top 10 causes of death. The 
interrelationship between TB and COPD is very complex. A 
substantial number of TB patients develop post-tubercular 
airway disease or TB-associated COPD. Although 
tuberculosis is a curable disease, it continues to be one of the 
leading infections associated with death in the world. The 
incidence rate of anti-tubercular drugs induced 
hepatotoxicity in India was found to be 2% to 28%6,8. COPD 
patients are also at high risk of developing pulmonary TB. 
COPD is a second most common comorbidity in patients with 
TB after diabetes. History of TB negatively impacts the long-
term course of COPD with early mortality and increased 
frequency of exacerbations. COPD also alters the clinical 
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presentation of TB and is a risk factor for increased 
morbidity and mortality from TB9-11. 
CASE REPORT 
 In this case report 65 year old male, weighing 47 kg, 
admitted to pulmonary ward of shri mahant indiresh 
hospital, Dehradun with chief complains of vomiting, 
cough with expectoration, loss of appetite, shortness of 
breath, fever (on & off) since 4 days. The patient was 
chronic alcoholic and consumed large amounts of 
alcohol with ATT drugs which may leads to changes 
liver conditions. He had a history of smear positive 
pulmonary koch’s 10 days back and was taking regular 
first line anti-tubercular drug therapy (Isoniazid, 
Rifampicin, Pyrazinamide and Ethambutol). On the 
same day, pulmonologist prescribed the following 
drugs to the patient after examination: 
1. Tablet Levocetirizine - 5mg HS 
2. Tablet Methyl Prednisolone -16mg BD 
3. Injection Pantoprazole - 40mg OD 
4. Tablet Hepamerz (L-Ornithine + L-Aspartate) 5mg 
(1Tab) BD 
5. Syrup Liv-52 2tsf TDS 
6. Nebulization 
7. 2 bottle normal saline i.v. - 100ml/hour 
8. Hold the CAT Ist ATT medication therapy. 
 On the 2nd day, alcoholic withdrawal symptoms such as 
delirium were seen in the patient. Blood pressure was 
recorded as 110/70 mmHg and pulse rate was 61/min. 
The patient was prescribed with injection Diazepam 
5mg in 10ml normal saline and start the modified anti-
tubercular therapy (levofloxacin 750mg OD, 
ehtambutol 800mg OD, streptomycin 0.75g I/M OD ), 
rest of the treatment was continued. 
 On the 3rd day, patient complaint of anxiety, so 
prescribed with tablet Lonazepam 0.25mg for 5 days. 
Blood pressure was normal i.e. 120/70 mmHg and 
pulse rate was 16/min with SPO2 concentration 99.2%.  
 On the 4th day, nutritional assessment was done and 
the patient was on soft liquid food, moderate protein 
and low fat liquid and same treatment was continued. 
 On 5th day, no fresh complaints were seen and 
temperature was normal, blood pressure was 110/80, 
respiratory rate was 20/min, pulse rate was 101/min 
with SPO2 concentration 98%. All liver function tests 
(LFT) reports were found normal. Patient was 
considered to be the case of Alcoholic liver disease 
(ALD) with hepatitis. 
 On 6th day, the patient was finally diagnosed as the case 
of anti-tubercular drug induced hepatitis. 
 On 7th day, physician stopped the modified ATT 
therapy, and started the CAT Ist DOTS Therapy 
(Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and 
Pyridoxine) with proper monitoring of routine LFT 
investigation. 
 The results of investigations were showed in Table-1.
 
 
Table 1: Laboratory Investigation 
S.No. Parameter 
Test value 
(Day-1) 
Test value 
(Last Day) 
Normal value 
1.  SGOT 712 58 17-59 IU/L 
2.  SGPT 868 85 9-52 IU/L 
3.  GGT 435 66 12-43 IU/L 
4.  Total Bilirubin 2.2 1.4 0.2-1.3 mg/dl 
5.  Direct Bilirubin 1.4 0.9 0.0-0.8 mg/dl 
6.  ALP 295 76 38-126 IU/L 
7.  PT 15 13 9.5-13.5 sec 
 
 
 On 8th day, patient was with no fresh complaints and 
plan for discharge was made. 
 On 9th day, patient was discharge with appropriate 
medication chart and patient counselling. The 
discharge medication includes: 
 Tablet Isoniazid 300mg OD - 1 week 
 Tablet Rifampin 450mg OD - 1 week 
 Tablet Ethambutol 800mg OD 1 week 
 Tablet Pyrazinamide 1200mg OD 1 week 
 Tablet Pyridoxine 40 mg ½ tab OD (HS) 1 week  
 Syrup Liv-52 2 tsf TDS 
 Tab Pantoprazole 40 mg OD 
 Review after 14 days in OPD with the LFT reports 
DISCUSSION 
Anti-TB drugs induced hepatotoxiciy is a serious problem 
and it was reported that 2-28% of TB patients experience 
drug related hepatotoxicity (DIH) during the course of the 
treatment. The incidence rate of drug induced 
hepatotoxicity in India is 8-36%. The higher incidence of 
DIH was found in the Asian countries which may be due to 
ethnic susceptibility, inherent peculiarity of drug 
metabolism and/or the presence of various known risk 
factors such as HBV infection, malnutrition, and 
alcoholism. According to a study, overall incidence of 
serious adverse effects was three times higher with 
pyrazinamide than with isoniazide, or rifampicin. 
Alcoholism is one of the main risk factor which aggravates 
the anti-TB induced hepatotoxicity. In this case, the patient 
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was chronic alcoholic and consumed large amounts of 
alcohol which may lead to following liver conditions - fatty 
liver, hepatitis and cirrhosis. In this case, hepatitis was 
seen in the patient. For all types of liver disease caused by 
alcohol, the main treatment is to stop consumption of 
alcohol completely. In our case, on withdrawal of alcohol 
the patient developed alcohol withdrawal syndrome such 
as delirium and the patient which was treated. Nutritional 
assessment was done and patient was on soft liquid food, 
moderate protein and low fat liquid during the course of 
the treatment. Taking all the information under 
consideration, a causality assessment of the entitled 
medical conditions was done by using Naranjo Causality 
Assessment Algorithm and the results indicated 
Antitubercular drugs and alcohol as possible cause 
hepatotoxicity. Upon normalization of patient conditions, 
physician restarted first line anti-tubercular drug therapy 
containing Rifampicin, Isoniazid, Pyrazinamide and 
Ethambutol with continued liver tonics. Routine 
monitoring of liver enzymes, total bilirubin were followed 
up till discharged. Upon discharge, patient was counseled 
regarding the medications and course of the treatment. 
CONCLUSION 
Patient developed hepatotoxicity and severe alcohol 
induced hepatitis following the administration of 1st line 
anti-TB drugs, which were administered for the treatment 
of pulmonary koch's. Following the withdrawal of alcohol, 
standard treatment and standard care, we were able to 
achieve a favorable outcome. As a clinical pharmacist and 
clinicians are need to be made aware of these potentially 
fatal adverse effects associated with anti-tubercular 
therapy via conduction of quality based seminars, 
conferences, published medical literature and learning 
programmes and health care camps. We needs and 
overcome the ATT induced hepatotoxicity by the following 
programmes like conduction of quality based seminars, 
health care camps, conferences, published medical 
literature and learning programmes. 
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